Filtered By:
Specialty: Cardiology
Drug: Lipitor

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 690 results found since Jan 2013.

Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264. PMID: 28974520 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2017 Category: Cardiology Authors: Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P Tags: Circulation Source Type: research

Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery
Aim: Atherosclerosis is the underlying reason for nearly all causes of coronary artery disease and peripheral arterial disease and many cases of stroke. Carotid color-Doppler ultrasonography is a popular tool for evaluating atherosclerosis of the carotid artery. The aim of this study was to generate a rabbit model of carotid arterial atherosclerotic stenosis and the subsequent investigating the effect of high-dose atorvastatin therapy on color-Doppler ultrasonography parameters in this model.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Hossein Mehrad, Manijhe Mokhtari-Dizaji, Hossein Ghanaati Source Type: research

High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
Conclusions Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.
Source: Revista Espanola de Cardiologia - July 15, 2017 Category: Cardiology Source Type: research

High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis.
CONCLUSIONS: High-dose atorvastatin did not show significant difference of MACEs in STEMI patients undergoing thrombolysis but showed significant improvement in immediate coronary flow depicted by ST-segment resolution. This benefit of high dose statin is to be weighed against greater myalgia, drug discontinuation and cost in Indian patients. PMID: 28822510 [PubMed - in process]
Source: Indian Heart J - July 1, 2017 Category: Cardiology Authors: Priti K, Agrawal A, Ranwa BL Tags: Indian Heart J Source Type: research

High versus Low dose Statin Therapy in Indian Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Thrombolysis
Conclusions High-dose atorvastatin did not show significant difference of MACEs in STEMI patients undergoing thrombolysis but showed significant improvement in immediate coronary flow depicted by ST-segment resolution. This benefit of high dose statin is to be weighed against greater myalgia, drug discontinuation and cost in Indian patients.
Source: Indian Heart Journal - May 31, 2017 Category: Cardiology Source Type: research

The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes and the response to atorvastatin and EZE combination was similar for both men and women. PMID: 28553847 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 29, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research

Atorvastatin inhibits cholesterol-induced caspase-3 cleavage through down-regulation of p38 and up-regulation of Bcl-2 in the rat carotid artery.
CONCLUSIONS: The resultant data suggest that the anti-apoptotic effect of AV could be partially mediated by the pro-inflammatory protein p38 MAPK and the anti-apoptotic protein Bcl-2 in the rat carotid artery. Atorvastatin can therefore be considered a target drug in the prevention or development of atherosclerotic events. PMID: 28498386 [PubMed - as supplied by publisher]
Source: Cardiovascular Journal of Africa - May 5, 2017 Category: Cardiology Authors: Bayatmakoo R, Rashtchizadeh N, Yaghmaei P, Farhoudi M, Karimi P Tags: Cardiovasc J Afr Source Type: research

Atorvastatin for high-risk statin-na ïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing noncardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high-risk statin-naïve patients is feasible and should be done to definitely establish the efficacy and safety of statin in this patient population.
Source: American Heart Journal - November 25, 2016 Category: Cardiology Source Type: research

Atorvastatin for High Risk Statin-Na ïve Patients Undergoing Noncardiac Surgery: The LOAD Randomized Trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing non-cardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high risk statin-naïve patients is feasible, and should be done to definitely establish the efficacy and safety of statin in this patient population. Clinical trial registration: Clinicaltrials.gov Identifier: NCT01543555
Source: American Heart Journal - November 9, 2016 Category: Cardiology Source Type: research

Comparative Effectiveness of Generic Atorvastatin and Lipitor(R) in Patients Hospitalized with an Acute Coronary Syndrome Health Services and Outcomes Research
Conclusions Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor® at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness.
Source: JAHA:Journal of the American Heart Association - April 18, 2016 Category: Cardiology Authors: Jackevicius, C. A., Tu, J. V., Krumholz, H. M., Austin, P. C., Ross, J. S., Stukel, T. A., Koh, M., Chong, A., Ko, D. T. Tags: Atrial Fibrillation, Quality and Outcomes Health Services and Outcomes Research Source Type: research

Atorvastatin inhibits miR-143 expression: A protective mechanism against oxidative stress in cardiomyocytes
Statins are unequivocally the most widely prescribed drug for the primary and secondary prevention of coronary artery disease worldwide [1]. Atorvastatin is the most commonly prescribed statin drug due to its lower therapeutic dose comared to others. The well-tolerated and high benefit–risk ration of atorvastain has been demonstrated in clinical trials [2]. Atorvastatin reduce the risk of myocardial infarction, stroke, and death, primarily inhibiting reactive oxygen species (ROS) [3].
Source: International Journal of Cardiology - March 1, 2016 Category: Cardiology Authors: Shanshan Tian, Wei Zhao, Di Yang, Yang Yu, Jiaqi Zou, Zhiyan Liu, Zhimin Du Tags: Correspondence Source Type: research

Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (From the Treating to New Targets TNT Study)
Statins may have nephroprotective as well as cardioprotective effects in patients with cardiovascular disease. In the Treating to New Targets (TNT) study (NCT00327691), patients with coronary heart disease (CHD) were randomized to atorvastatin 10- or 80-mg/day and followed for 4.9 years. The relationship between intra-study change in estimated glomerular filtration rate (eGFR) from baseline and the risk of major cardiovascular events (MCVE, defined as CHD death, nonfatal non-procedure-related myocardial infarction, resuscitated cardiac arrest or fatal or nonfatal stroke) was assessed among 9500 patients stratified by renal...
Source: The American Journal of Cardiology - January 28, 2016 Category: Cardiology Authors: James Shepherd, Andrei Breazna, Prakash C. Deedwania, John C. LaRosa, Nanette K. Wenger, Michael Messig, Daniel J. Wilson, Treating to New Targets Steering Committee and Investigators Source Type: research

Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats
This study determined the structural and functional changes in the middle cerebral arteries (MCA) during the progression of MetS and the effects of chronic pharmacological interventions on mitigating vascular alterations in obese Zucker rats (OZR), a translationally relevant model of MetS. The reactivity and wall mechanics of ex vivo pressurized MCA from lean Zucker rats (LZR) and OZR were determined at 7–8, 12–13, and 16–17 wk of age under control conditions and following chronic treatment with pharmacological agents targeting specific systemic pathologies. With increasing age, control OZR demonstrated r...
Source: AJP: Heart and Circulatory Physiology - December 1, 2015 Category: Cardiology Authors: Brooks, S. D., DeVallance, E., d'Audiffret, A. C., Frisbee, S. J., Tabone, L. E., Shrader, C. D., Frisbee, J. C., Chantler, P. D. Tags: CALL FOR PAPERS Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke
There are no studies that compared the effects of different intensities of statin treatment on the long-term outcome of patients with recent ischemic stroke. We aimed to evaluate these effects. Methods: We prospectively studied 436 consecutive patients who were discharged after acute ischemic stroke (39.2% males, age 78.6±6.7 years). Statin treatment was categorized in equipotent doses of atorvastatin. One year after discharge, the functional status was assessed with the modified Rankin scale (mRS).
Source: Atherosclerosis - September 2, 2015 Category: Cardiology Authors: Konstantinos Tziomalos, Vasilios Giampatzis, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Stella-Maria Angelopoulou, Filitsa Konstantara, Christos Savopoulos, Apostolos I. Hatzitolios Source Type: research